RecruitingPhase 3

A Study of SHR-A1811 in Subjects With Ovarian Cancer

China300 participantsStarted 2025-03-13

Plain-language summary

This is an open-label study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with ovarian cancer.

Age range18 Years – 75 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. The subjects voluntarily joined the study and signed the Informed consent forms (ICF).
✓. Measurable disease, as defined by RECIST v1.1.
✓. The Eastern Cancer Cooperative Group (ECOG) performance status of 0 or 1.
✓. Life expectancy ≥ 12 weeks.

Progression free survival (PFS)

Timeframe: From day 1 to 10 months.

NCT IDNCT06828354

SponsorJiangsu HengRui Medicine Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2027-05

Yuanchao Wang